Apellis Pharmaceuticals, Inc. (APLS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
APLS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
APLS Revenue Analysis (2014–2025)
As of February 28, 2026, Apellis Pharmaceuticals, Inc. (APLS) generated trailing twelve-month (TTM) revenue of $689.4 million, reflecting significant decline in growth of -153.9% year-over-year. The most recent quarter (Q4 2025) recorded $-114,486,000 in revenue, down 125.0% sequentially.
Looking at the longer-term picture, APLS's 5-year compound annual growth rate (CAGR) stands at +22.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $781.4 million in 2024.
Revenue diversification analysis shows APLS's business is primarily driven by Product (69%), and Licensing And Other Revenue (31%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY), APLS has underperformed the peer group in terms of revenue growth. Compare APLS vs ARGX →
Peer Comparison
Compare APLS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| APLSCurrent | $689M | -153.9% | +22.4% | 8.0% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $689.4M | -11.8% | $587.1M | 85.2% | $55.4M | 8.0% |
| 2024 | $781.4M | +97.0% | $663.6M | 84.9% | $-164,979,000 | -21.1% |
| 2023 | $396.6M | +425.8% | $338.1M | 85.2% | $-517,121,000 | -130.4% |
| 2022 | $75.4M | +13.3% | $69.8M | 92.5% | $-594,613,000 | -788.4% |
| 2021 | $66.6M | -73.4% | $61.4M | 92.2% | $-536,277,000 | -805.7% |
| 2020 | $250.6M | - | $225.6M | 90.0% | $-213,726,000 | -85.3% |
| 2019 | $0 | - | $-595,449 | - | $-288,015,253 | - |
| 2018 | $0 | - | $-127,925,000 | - | $-127,925,000 | - |
| 2017 | $0 | - | $-50,767,000 | - | $-50,767,000 | - |
| 2016 | $0 | - | $0 | - | $-27,282,000 | - |
See APLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare APLS vs AGIO
See how APLS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is APLS's revenue growth accelerating or slowing?
APLS revenue declined -153.9% year-over-year, contrasting with the 5-year CAGR of +22.4%. TTM revenue fell to $689M. This reverses the prior growth trend.
What is APLS's long-term revenue growth rate?
Apellis Pharmaceuticals, Inc.'s 5-year revenue CAGR of +22.4% reflects the variable expansion pattern. Current YoY growth of -153.9% is below this long-term average.
How is APLS's revenue distributed by segment?
APLS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.